.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Baxter
Cipla
Julphar
Deloitte
Mallinckrodt
QuintilesIMS
McKesson
US Army
Chinese Patent Office

Generated: July 22, 2017

DrugPatentWatch Database Preview

Bausch And Lomb Company Profile

« Back to Dashboard

What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?

BAUSCH AND LOMB has seventy-five approved drugs.

There are twenty-two US patents protecting BAUSCH AND LOMB drugs.

There are one hundred and forty-two patent family members on BAUSCH AND LOMB drugs in twenty-two countries.

Summary for Applicant: Bausch And Lomb

Patents:22
Tradenames:64
Ingredients:53
NDAs:75
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
LEVOBUNOLOL HYDROCHLORIDE
levobunolol hydrochloride
SOLUTION/DROPS;OPHTHALMIC074307-001Mar 4, 1994ATRXNoNo► Subscribe► Subscribe
Bausch And Lomb
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
hydrocortisone; neomycin sulfate; polymyxin b sulfate
SOLUTION/DROPS;OTIC064053-001Dec 29, 1995ATRXNoNo► Subscribe► Subscribe
Bausch And Lomb
CROMOLYN SODIUM
cromolyn sodium
SOLUTION;INHALATION075585-001Dec 21, 2000ANRXNoNo► Subscribe► Subscribe
Bausch And Lomb
GENTAMICIN SULFATE
gentamicin sulfate
SOLUTION/DROPS;OPHTHALMIC064048-001May 11, 1994ATRXNoYes► Subscribe► Subscribe
Bausch And Lomb
ERYTHROMYCIN
erythromycin
OINTMENT;OPHTHALMIC064067-001Jul 29, 1994ATRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 20045,540,930*PED► Subscribe
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 20045,747,061*PED► Subscribe
Bausch And Lomb Inc
XIBROM
bromfenac sodium
SOLUTION/DROPS;OPHTHALMIC021664-001Mar 24, 20054,910,225► Subscribe
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 19984,996,335*PED► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 20095,447,926► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAUSCH AND LOMB drugs

Drugname Dosage Strength Tradename Submissiondate
bepotastine besilate
Ophthalmic Solution1.5%
BEPREVE
9/9/2013
bromfenac sodium
Ophthalmic Solution0.07%
PROLENSA
7/26/2013
timolol maleate
Ophthalmic Solution0.5%
ISTALOL
10/19/2012

Non-Orange Book Patents for Bausch And Lomb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,893Topical treatment for prevention of ocular infections► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
8,252,307Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
8,883,825Aqueous liquid preparations and light-stabilized aqueous liquid preparations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bausch And Lomb Drugs

Country Document Number Estimated Expiration
Japan2012521433► Subscribe
Japan2011063619► Subscribe
JapanWO2004011001► Subscribe
European Patent Office0969812► Subscribe
South Korea20110122202► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bausch And Lomb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/014United Kingdom► SubscribePRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
2015000061Germany► SubscribePRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016 00031Denmark► SubscribePRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
2015 00043Denmark► SubscribePRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
McKinsey
UBS
Fish and Richardson
Daiichi Sankyo
Fuji
Citi
Queensland Health
Dow
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot